Skip to main content
NUVB
NYSE Life Sciences

Nuvation Bio Finalizes $250M Convertible Note Offering at 35% Premium

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$5.5
Mkt Cap
$1.973B
52W Low
$1.81
52W High
$9.75
52W Position info
204% above low
Off High info
44% below high
Rel. Volume info
6.9× avg
Market data snapshot near publication time

NUVB has more than doubled off its 52-week low of $1.81 on elevated volume (6.9× avg).

Summary

Nuvation Bio finalized a $250 million convertible senior note offering with a 35% premium conversion price, using proceeds to repay debt and for general corporate purposes, enhancing financial stability.


Key Events · Financing and Capital Events · NUVB

  • Finalized Convertible Note Offering

    Nuvation Bio finalized an offering of $250 million in 0.75% Convertible Senior Notes due 2032, with an option for underwriters to purchase an additional $37.5 million.

  • Premium Conversion Price

    The initial conversion price is approximately $7.84 per share, representing a 35% premium over the Class A common stock's last reported sale price of $5.81 on June 25, 2026.

  • Use of Proceeds

    Net proceeds of approximately $241.2 million (or $277.6 million if the over-allotment option is fully exercised) will be used to repay $50 million in existing secured debt, fund $14.9 million for capped call transactions, and for general corporate purposes.

  • Dilution Mitigation

    Capped call transactions were entered into to generally reduce potential dilution to Class A common stock upon conversion and/or offset cash payments, subject to a cap price of $10.4580.


Analysis · NUVB · Life Sciences

Nuvation Bio has finalized its offering of $250 million in 0.75% Convertible Senior Notes due 2032, with an initial conversion price of approximately $7.84 per share. This conversion price represents a significant 35% premium over the Class A common stock's last reported sale price of $5.81 on June 25, 2026. The company plans to use the net proceeds to repay $50 million in existing secured debt and for general corporate purposes, including funding capped call transactions to mitigate potential dilution. This substantial capital raise, secured on favorable terms, strengthens the company's balance sheet and provides additional financial flexibility, following strong Q1 2026 results.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 45% of the 1400 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NUVB was trading at $5.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $1.81 to $9.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NUVB - Latest Insights

NUVB
Nov 04, 2026, 4:05 PM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $4.78
Real-time Price: $4.19 info
Change: -$0.5889 (-12%) info
Market Cap: $1.465B info
NUVB
Sep 17, 2026, 7:30 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $5.78
Real-time Price: $4.19 info
Change: -$1.59 (-28%) info
Market Cap: $1.465B info
NUVB
Aug 20, 2026, 8:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $7.23
Real-time Price: $4.19 info
Change: -$3.04 (-42%) info
Market Cap: $1.465B info
NUVB
Aug 06, 2026, 7:53 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $6.16
Real-time Price: $4.19 info
Change: -$1.97 (-32%) info
Market Cap: $1.465B info
NUVB
Aug 06, 2026, 6:55 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.01
Real-time Price: $4.19 info
Change: -$1.82 (-30%) info
Market Cap: $1.465B info